Search

Your search keyword '"Infante, Jon"' showing total 138 results

Search Constraints

Start Over You searched for: Author "Infante, Jon" Remove constraint Author: "Infante, Jon" Database Unpaywall Remove constraint Database: Unpaywall
138 results on '"Infante, Jon"'

Search Results

1. In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson

2. Where Should I Draw the Line: PET-Driven, Data-Driven, or Manufacturer Cut-Off?

4. Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph disease

5. Influence of Physiological Variables and Comorbidities on Plasma Aβ40, Aβ42, and p-tau181 Levels in Cognitively Unimpaired Individuals

6. Stage‐dependent biomarker changes in spinocerebellar ataxia type 3

7. Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform

9. Genome-wide structural variant analysis identifies risk loci for non-Alzheimer’s dementias

10. Stage-dependent biomarker changes in spinocerebellar ataxia type 3

11. Differential serum microRNAs in premotor LRRK2 G2019S carriers from Parkinson’s disease

12. Analysis of retinal nerve layers in idiopathic, LRRK2-associated Parkinson's disease and unaffected carriers of G2019S mutation

14. Intermediate and ExpandedHTTAlleles and the Risk for α‐Synucleinopathies

15. Differential Temporal Dynamics of Axial and Appendicular Ataxia in SCA3

16. Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3

17. Repeat expansion size predicts age of onset in RFC1 CANVAS and disease spectrum (S29.005)

18. Sensor-based gait analysis in the premotor stage of LRRK2 G2019S-associated Parkinson's disease

19. Smoking is associated with age at disease onset in Parkinson's disease

21. Characterization of Lifestyle in Spinocerebellar Ataxia Type 3 and Association with Disease Severity

22. Serial DaT‐SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8 years’ follow‐up

24. Regional Brain and Spinal Cord Volume Loss in Spinocerebellar Ataxia Type 3

25. Polyglutamine-expanded ataxin-3: a target engagement marker for Spinocerebellar ataxia type 3 in peripheral blood

27. Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis

30. Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease

31. Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study

34. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies

35. Reply to: “Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion”

37. POLR3A-related spastic ataxia: new mutations and a look into the phenotype

38. Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism

41. Prediction of Survival With Long‐Term Disease Progression in Most Common Spinocerebellar Ataxia

43. LRP10 in α-synucleinopathies

44. Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias

46. Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study

47. Body Mass Index Decline Is Related to Spinocerebellar Ataxia Disease Progression

50. Charcot-Marie-Tooth disease type 2G redefined by a novel mutation inLRSAM1

Catalog

Books, media, physical & digital resources